Top

Published in:

05-07-2022 | Atrial Fibrillation | Original Article

Declines in serum uric acid level after catheter ablation of atrial fibrillation

Authors: Daisetsu Aoyama, Hiroyasu Uzui, Takayuki Sekihara, Tomoya Eguchi, Kanae Hasegawa, Toshihiko Tsuji, Tatsuhiro Kataoka, Moeko Nagao, Shota Kakehashi, Moe Mukai, Takayoshi Aiki, Junya Yamaguchi, Yuichiro Shiomi, Naoto Tama, Yoshitomo Fukuoka, Kentaro Ishida, Hiroshi Tada

Published in: Heart and Vessels | Issue 12/2022

Abstract

Background

Few studies have examined whether catheter ablation for AF patients improves biomarkers other than serum levels of brain natriuretic peptide (BNP) and renal function. This study was to explore whether catheter ablation for atrial fibrillation (AF) patients affects uric acid (UA), glucose and lipid metabolism.

Methods and results

A total of 206 patients (66.6 ± 10.4 years; 132 men) who underwent initial AF ablation without changes to oral medications were included. Baseline BNP and UA levels significantly decreased at 1 year after ablation (p < 0.05 each). Changes in UA level correlated significantly with pre-procedural UA level (r = 0.57). In multivariable logistic regression modeling, pre-procedural UA level, persistent AF, and hemoglobin A1c (p < 0.05 each) were independent predictors of post-procedural UA level decline. Significant improvements in both persistent and paroxysmal AF patients were identified, and the magnitude of post-procedural serum UA level decline after ablation (ΔUA) was significantly greater in patients with persistent AF (0.8 ± 1.0 mg/dl) than in those with paroxysmal AF (0.2 ± 0.8 mg/dl, p < 0.001). Of the 48 patients with high UA level before procedure, 28 patients showed improvement in UA level to normal range.

Conclusions

Catheter ablation for AF patients significantly improved serum UA levels without obvious influences of heart failure, renal function, or inflammation, suggesting that AF ablation may be effective for AF patients with hyperuricemia.

Trial registration The study was approved by the Research Ethics Committee of University of Fukui (no. 20210132) and clinical trial registration (UMIN000044669).

Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale, (2016) Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 133:1637–1644CrossRef

Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, Usui A, Okishige K, Kusano K, Kumagai K, Goya M, Kobayashi Y, Shimizu A, Shimizu W, Shoda M, Sumitomo N, Seo Y, Takahashi A, Tada H, Naito S, Nakazato Y, Nishimura T, Nitta T, Niwano S, Hagiwara N, Murakawa Y, Yamane T, Aiba T, Inoue K, Iwasaki Y, Inden Y, Uno K, Ogano M, Kimura M, Sakamoto S, Sasaki S, Satomi K, Shiga T, Suzuki T, Sekiguchi Y, Soejima K, Takagi M, Chinushi M, Nishi N, Noda T, Hachiya H, Mitsuno M, Mitsuhashi T, Miyauchi Y, Miyazaki A, Morimoto T, Yamasaki H, Aizawa Y, Ohe T, Kimura T, Tanemoto K, Tsutsui H, Mitamura H (2021) JCS/JHRS 2019 guideline on non-pharmacotheraopy of cardiac arrhythmias. Cric J 85:1104–1244

Friberg L, Tabrizi F, Englund A (2016) Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J 37:2478–2487CrossRef

Yamada T, Murakami Y, Okada T, Yoshida N, Toyama J, Yoshida Y, Tsuboi N, Inden Y, Hirai M, Murohara T (2007) Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysimal persistent, and permanent atrial fibrillation. Europace 9(9):770–774CrossRef

Takahashi Y, Takahasi A, Kuwahara T, Okubo K, Fujino T, Takagi K, Nakashima E, Kamiishi T, Hikita H, Hirao K, Isobe M (2011) Renal function after catheter ablation of atrial fibrillation. Circulation 124(22):2380–2387CrossRef

Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S (2004) Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa. Japan Hypertens Res 27(4):227–233CrossRef

Li S, Cheng J, Cui L, Gurol ME, Bhatt DL, Fonarow GC, Benjamin EJ, Xing A, Xia Y, Wu S, Gao X (2019) Cohort study of repeated measurenments of serum urate and risk of incidence atrial fibrillation. J Am Heart Assoc 8(13):e012020CrossRef

Liu Z, Que S, Zhou L, Zheng S (2015) Dose-serponse relationship of serum uric acid with metabolic syndrome and non-alcohlic fatty liver disease incidence: a meta-anaysis of prospective study. Sci Rep 5:14325CrossRef

Zhao J, Liu T, Korantzopoulos P, Letsas KP, Zhang E, Yang Y, Zhang Z, Qui J, Li J, Li G (2016) Association between serum uric acid and atrial fibrillation recurrence following catheter ablation: a meta-analysis. Int J Cardiol 204:103–105CrossRef

10.

Gou X, Zhang S, Yan X, Chen Y, Yu R, Long D, Sang C, Du X, Dong J, Ma C (2014) Postablation neutrophil/lymphocyte ratio correlates with arrhythmia recurrence after catheter ablation of lone atrial fibrillation. Chin Med J (Engl) 127(6):1033–1038

11.

Maharani N, Ting YK, Cheng J, Hasegwa A, Kurata Y, Li P, Nakayama Y, Ninomiya H, Ikeda N, Morikawa K, Yamamoto K, Makita N, Yamashita T, Shirayoshi Y, Hisatome I (2015) Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes. Circ J 79(12):2659–2668CrossRef

12.

Doehner W, Landmesse U (2011) Xanthine oxidase and uric acid in cardiovascular disesase: clinical impact and therapeutic options. Semin Nephrol 31(5):433–440CrossRef

13.

CarnesChungNakayamaNakayamaBaligaPiaoKanderianPavia CAMKTHRSSAS, HamlinMcCarthy BauerVamWagoner RLPMJADR (2001) Ascorbate attenuates atrial pacing-induced perroxynitrite formation and electrical remodeling and decreases the incidence of postoperateci atrial fibrillation. Circ Res 89(6):E32–E38

14.

Gonzalez RD, Treuer A, Sun QA, Stamler JS, Hare JM (2009) S-Nitrosylation of caradiac ion channels. J Cardiovasc Phamacol 54(3):188–195CrossRef

15.

Ono K (2019) How is uric acid related to atrial fibrillation? Circ J 83(4):705–706CrossRef

16.

Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reducrtion of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51(3):321–325CrossRef

17.

Ndrepepa G, Braun S, Hasse HU, Schulz S, Ranftl S, Hadamitzky M, Mehilli J, Schömig A, Kastrati A (2012) Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol 109(9):1260–1265CrossRef

18.

Shibata Y, Shirakabe A, Okazaki H, Matsushita M, Goda H, Shigihara S, Asano K, Kiuchi K, Tani K, Murase T, Nakamura T, Kobayashi N, Hata N, Asai K, Shimizu W (2020) Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care. Heart Vessels 35(10):1390–1400CrossRef

19.

Nishino M, Mori N, Yoshimura T, Nakamura D, Lee Y, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Tanouchi J, Yamada Y (2014) Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm. Heart Vessels 29(2):186–190CrossRef

20.

Seki H, Kaneko H, Morita H, Itoh H, Morita K, Matsuoka S, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Yano Y, Nakamura S, Node K, Yasunaga H, Komuro I (2021) Relation of serum uric acid and cardiovascular events in young adults aged 20–49 years. Am J Cardiol 152:150–157CrossRef

21.

Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y (2011) Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol 12:31CrossRef

22.

Thanassoulis G, Brophy JM, Richard H, Pilote L (2010) Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 170(15):1358–1364CrossRef

Title: Declines in serum uric acid level after catheter ablation of atrial fibrillation
Authors: Daisetsu Aoyama
Hiroyasu Uzui
Takayuki Sekihara
Tomoya Eguchi
Kanae Hasegawa
Toshihiko Tsuji
Tatsuhiro Kataoka
Moeko Nagao
Shota Kakehashi
Moe Mukai
Takayoshi Aiki
Junya Yamaguchi
Yuichiro Shiomi
Naoto Tama
Yoshitomo Fukuoka
Kentaro Ishida
Hiroshi Tada
Publication date: 05-07-2022
Publisher: Springer Japan
Keyword: Atrial Fibrillation
Published in: Heart and Vessels / Issue 12/2022
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-022-02108-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Declines in serum uric acid level after catheter ablation of atrial fibrillation

Abstract

Background

Methods and results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2022

Bone morphogenetic protein-4 system expression in human coronary artery endothelial and smooth muscle cells under dynamic flow: effect of medicated bioresorbable vascular scaffolds at low and normal shear stress

Clinical outcomes of grafted vs. percutaneous axillary intra-aortic balloon pump support as a bridge to transplantation: a propensity score-matched analysis

Acknowledgement to reviewers

Transcranial Doppler for stratification of high-risk morphology of patent foramen ovale in patients with cryptogenic stroke

Cluster analysis of extracellular matrix biomarkers predicts the development of impaired systolic function within 1 year of acute myocardial infarction

Trends in prognosis after hospitalization for acute heart failure in Kurashiki Central hospital 2015–2018: single-center prospective study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page